阿尔茨海默病:探索认知衰退的景观
Rumiana Tenchov1, Janet M Sasso1, Qiongqiong Angela Zhou1
1CAS, a division of the American Chemical Society, Columbus Ohio 43210, United States.
ACS chemical neuroscience
|October 11, 2024
概括
本综述总结了阿尔茨海默病研究进展,涵盖遗传因素,生物标志物和治疗策略. 它强调了早期诊断和疾病修饰治疗的进展,以对抗这种神经退行性疾病.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,导致认知能力下降和记忆力丧失.
- 病理包括粉样β斑块,陶,神经炎症和突触功能障碍.
- 遗传因素如APP,PSEN1,PSEN2突变和APOE ε4增加了AD风险.
研究的目的:
- 分析CAS内容收集数据并总结阿尔茨海默病的研究进展.
- 提供有关AD研究当前知识,进展和发展的见解.
- 审查与阿尔茨海默病作斗争的新兴概念,战略和挑战.
主要方法:
- 来自CAS内容集的出版景观和研究数据的分析.
- 对AD的遗传风险因素,药理标和并发性疾病的审查.
- 检查临床应用,开发管道和用于AD的药物重新用途.
主要成果:
- 确定阿尔茨海默病的关键研究领域和趋势.
- 遗传贡献和新兴治疗目标的概述.
- 评估当前治疗局限性和疾病修饰疗法的前景.
结论:
- 生物标志物的进步对于早期诊断和治疗监测至关重要.
- 开发针对AD潜在机制的疾病修饰疗法是重点关注的重点.
- 持续的研究和战略努力对于有效打击阿尔茨海默病至关重要.
更多相关视频
相关概念视频
Alzheimer's Disease: Overview
449
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
449
Dementia
97
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
97
Alzheimer's Disease: Treatment
166
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
166
Cognitive Development During Adulthood
65
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
65
Long-term Depression
2.5K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.5K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
106
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
106


